nasic 5%/0,l% nasal spray, solution
cassella-med gmbh & co.kg - Декспантенол, Ксилометазолин - 5%/0,l% nasal spray, solution
nasic kids 5%/0,05% nasal spray, solution
cassella-med gmbh & co.kg - Ксилометазолин - 5%/0,05% nasal spray, solution
mometasone furoate cipla 50 micrograms/actuation nasal spray, suspension
cipla (eu) limited - Мометазон - 50 micrograms/actuation nasal spray, suspension
olynth hydra 0,1% nasal spray, solution
mcneil products limited - Ксилометазолин - 0,1% nasal spray, solution
xylorhin 0,055% nasal spray, solution
omega pharma limited - Ксилометазолин - 0,055% nasal spray, solution
xymeral 1 mg/ml nasal spray, solution
Майлан ЕООД - 1 mg/ml nasal spray, solution
xymeral 0,5 mg/ml nasal spray, solution
Майлан ЕООД - 0,5 mg/ml nasal spray, solution
otrivin menthol 0,1% nasal spray, solution
novartis consumer health gmbh - Ксилометазолин - 0,1% nasal spray, solution
tyruko
sandoz gmbh - натализумаб - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 и 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri
biogen netherlands b.v. - натализумаб - Множествена склероза - Селективни имуносупресори - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 и 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.